A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Amifampridine (Primary)
- Indications Lambert-Eaton myasthenic syndrome
- Focus Therapeutic Use
- Sponsors Catalyst Pharmaceutical
- 03 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
- 03 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
- 30 Aug 2017 According to a Catalyst Pharmaceuticals media release, expects to complete enrollment shortly and to announce top-line results in the fourth quarter of this year.